RESUMEN
The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.
Asunto(s)
Infecciones por Alphavirus/prevención & control , Alphavirus/genética , Alphavirus/inmunología , Replicón , Vacunas Virales/genética , Alphavirus/fisiología , Animales , Células Dendríticas/inmunología , Células Dendríticas/fisiología , Células Dendríticas/virología , Regulación Viral de la Expresión Génica , Humanos , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Vacunas de ADN/normas , Tropismo Viral , Vacunas Virales/inmunología , Vacunas Virales/normasRESUMEN
A single-cycle, propagation-defective replicon particle (RP) vaccine expressing a swine influenza virus hemagglutinin (HA) gene was constructed and evaluated in several different animal studies. Studies done in both the intended host (pigs) and non-host (mice) species demonstrated that the RP vaccine is not shed or spread by vaccinated animals to comingled cohorts, nor does it revert to virulence following vaccination. In addition, vaccinated pigs develop both specific humoral and IFN-γ immune responses, and young pigs are protected against homologous influenza virus challenge.